JUPITER NEUROSCIENCES, INC.

Jupiter Neurosciences, Inc. has filed an S-1 registration statement to register an additional 16,000,000 common shares for resale by Yorkville, its selling stockholder. These shares are part of a Standby Equity Purchase Agreement (SEPA) under which the company may receive up to $17.2 million from future sales to Yorkville, in addition to $2.8 million already received. The financing arrangement also includes $6.0 million in Pre-Paid Advances from Yorkville in exchange for Convertible Notes, which carry an 8% annual interest rate and mature on October 24, 2026. Proceeds from these sales are intended to support the company's Phase 2 trial for Parkinson's Disease and accelerate marketing for its Nugevia product line.

Jupiter Neurosciences, Inc. announced its 2026 virtual Annual Meeting of Stockholders to be held on July 22, 2026. Stockholders will vote on the election of seven directors, including two new nominees, following a recent resignation and a director not standing for re-election. Key proposals also include the ratification of Cherry Bekaert LLP as the independent auditor, an amendment to increase shares authorized under the 2025 Equity Incentive Plan by 5,250,000, and an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1:10 and 1:100.

Jupiter Neurosciences, Inc. announced that Allison W. Brady resigned from its Board of Directors, effective June 17, 2026. Ms. Brady also stepped down from her positions on the Audit Committee and the Compensation Committee. The company stated that her decision was not a result of any disagreement with the company's operations, policies, or practices. The vacant Board seat will be filled at the company's annual meeting on July 22, 2026.

Jupiter Neurosciences, Inc. announced the promotion of Alison Silva to Chief Operating Officer and President, effective June 5, 2026. Her base salary was increased to $340,200 from $315,000. Additionally, Ms. Silva received a one-time grant of options to purchase 600,000 shares. The company also approved discretionary bonus stock options for several executives, including Christer Rosén (747,783 options), Alison Silva (427,304 options), and Saleem Elmasri (325,565 options), among others. Independent non-employee directors each received options to purchase 100,000 shares.

Jupiter Neurosciences announced that patient enrollment has commenced for its Phase 2a RESET clinical trial (NCT07592767) evaluating JOTROL™ for Parkinson's Disease, with first patient dosing expected soon. JOTROL™ is an investigational oral candidate targeting underlying biological drivers of neurodegeneration in a market with no current disease-modifying therapies. The global Parkinson's Disease treatment market, valued at $5.65 billion in 2024, is projected to grow to $7.58 billion by 2030. The multi-center, randomized, double-blind, placebo-controlled study will enroll 30 patients, with completion anticipated in H1 2027.

Jupiter Neurosciences, Inc. announced the closing of a registered direct offering, raising approximately $2.0 million through the sale of 7,142,858 shares of common stock. This capital infusion significantly reduces the company's debt, improving its balance sheet, and extends its cash runway. The funds will enable Jupiter to comfortably execute its Parkinson's Phase 2a trial and advance the transaction with PharmALA (ALA-002-MDMA), positioning the company for future financing opportunities.

Jupiter Neurosciences, Inc. announced the pricing of a registered direct offering to raise approximately $2.0 million in gross proceeds. The company agreed to sell 7,142,858 shares of common stock at a price of $0.28 per share to investors. D. Boral Capital LLC is acting as the exclusive placement agent for the offering, which is expected to close around May 21, 2026.

Jupiter Neurosciences, Inc. announced it has entered into a securities purchase agreement for a registered direct offering. The company will sell 7,142,858 shares of common stock, expecting to raise approximately $2.0 million in gross proceeds. The offering is anticipated to close around May 21, 2026, and the funds will support its therapeutic pipeline targeting central nervous system disorders and neuroinflammation. D. Boral Capital LLC is serving as the exclusive placement agent.

Jupiter Neurosciences entered a non-binding term sheet with PharmAla Biotech to acquire exclusive, perpetual U.S. licensing rights for ALA-002, a next-generation MDMA formulation. The deal includes an upfront payment of $3.33 million ($1.5M cash, $1.83M equity), potential development milestones of $23.33 million, and commercialization milestones of $73.33 million, plus a perpetual 3% royalty on U.S. net sales. This transaction positions Jupiter in the growing psychedelic therapeutics market, following a recent Executive Order accelerating psychedelic medicine. The definitive agreement is expected within 90 days, subject to due diligence and other conditions.

Jupiter Neurosciences, Inc. announced a term sheet to acquire exclusive, perpetual United States licensing rights to ALA-002, a lead drug candidate from PharmAla Biotech Holdings Inc. The deal involves an upfront payment of $3.33 million, consisting of $1.50 million in cash and $1.83 million in JUNS common stock, plus future milestone payments and royalties. This strategic move positions Jupiter in the rapidly growing psychedelic therapeutics market, bolstered by President Trump's recent Executive Order to accelerate psychedelic medicine.